Govt Regulations
CDSCO pilots AI while building one digital spine for drug regulation
By Arjun
·
6 Aug 12:06 AM
·
Via The Hindu BusinessLine
India's drug regulator is piloting artificial intelligence across CDSCO workflows while preparing the first phase of an end-to-end digital platform within about 18 months. Drugs Controller General Rajeev Singh Raghuvanshi said the system would link research, manufacturing, approvals, distribution, and post-market surveillance. CDSCO already claims more than 99 percent of processes are digitised and plans QR checks on GMP and COPP certificates. Why it matters: New Delhi is treating AI as infrastructure for how medicines are cleared. Caveat: the AI pilots are still lightly specified, and the platform remains a timeline, not a finished rollout.
Read the original →
Our summary is original writing; the full story belongs to The Hindu BusinessLine.
Sign in or create a free account to keep this story in a bookmark folder.
Karnataka chief minister D.K. Shivakumar met an Anthropic delegation to explore a long-term partnership covering governance, higher education, healthcare, research, and the state's startup base, The Economic Times reported. Talks include Claude certification under the NIPUNA skilling push, a possible 100-day roadmap with milestones, and subsidised Claude access for institutions such as VTU. The outreach follows plans for India's first government-led AI university and incubation centre, with IT minister Priyank Kharge helping convene global AI firms. Anthropic attendees included international policy and India leads. These are exploratory discussions, not a signed MoU, so curriculum, subsidy terms, and university legislation can still change.
Eleven industry and patient groups have urged Health Minister J.P. Nadda to rethink the draft Drugs, Medical Devices and Cosmetics Bill, 2026, arguing it still regulates medical devices, including AI-enabled diagnostics, as if they were pharmaceuticals. The Economic Times reports their August 8 letter objects to drug-style labels such as adulterated or spurious and to one-to-seven-year prison terms for labelling or engineering lapses even when no patient is harmed. Associations want a standalone Medical Devices Act, an independent regulator, and risk-based enforcement closer to FDA and EU MDR practice. The draft is in inter-ministerial consultation, so the final statute could still change.
India's Supreme Court on Thursday asked the Centre to consider suggestions for binding guidelines on AI ethics, transparency in surveillance and content moderation, algorithmic impact assessments, and human oversight of high-risk government systems, The Economic Times reported. A bench led by Chief Justice Surya Kant disposed of the PIL without ruling on the merits, saying the issues sit in a technical policy domain, and told the petitioner to send the writ as a representation. That matters as courts keep pushing AI governance toward MeitY. The caveat is that the order creates no new statute yet, only a duty to consider the representation.
A Nature paper by Kasirzadeh and Gabriel, published Aug. 12, proposes agentic profiles that score AI agents on autonomy, efficacy, goal complexity, and generality. Each axis, they argue, raises different design and oversight questions, helping developers and policymakers separate narrow assistants from highly autonomous general-purpose systems. The taxonomy aims to make governance debates less one-size-fits-all as agents gain tools and longer horizons. That matters while regulators lack shared agent-risk vocabulary. The caveat is that a taxonomy alone creates no enforceable thresholds or audits.